A possible explanation might be that the serum levels of AOPP and the markers of ferroptosis reflect intense oxidative damage induced by sorafenib, while the present study explored the transcriptional regulation of MT1 in cancer cells, and therefore the impact of sorafenib at lower, sub-cytotoxic concentrations. This evidence concerns the gene MT1B and cancer.